Please login to the form below
Janssen
This page shows the latest Janssen news and features for those working in and with pharma, biotech and healthcare.
J&J and Pfizer quietly resolve Remicade biosimilar lawsuit
Janssen [J&J’s pharma division] has always been and remains committed to ensuring that our medicines – including Remicade – are accessible for patients and doctors who choose them.
Latest news
-
J&J’s COVID-19 vaccine shows ‘strong’ activity against Delta variant
In addition, we observe a persistent and particularly robust, durable cellular immune response,” said Mathai Mammen, global head, Janssen Research &Development, Johnson &Johnson.
-
CHMP recommends eight new medicines for EU approval
Two generic medicines also received positive opinions from the CHMP: Abiraterone Mylan (abiraterone acetate), a generic of Janssen’s Zytiga, for the treatment of metastatic prostate cancer and Fingolimod Mylan (fingolimod),
-
J&J’s Darzalex shows ‘significant’ survival benefit in newly diagnosed multiple myeloma
backbone therapy in the treatment of multiple myeloma," said Craig Tendler, vice president, late development and global medical affairs, oncology, Janssen Research &Development.
-
J&J exits $1.6bn blood cancer drug licensing deal with argenx
Final results from Janssen's clinical studies of cusatuzumab will be presented in the future,” the statement said. ... We have valued the productive collaboration with Janssen that has advanced our understanding of cusatuzumab and its role in AML
-
J&J's single-dose COVID-19 vaccine secures approval from the UK’s MHRA
Although the UK Vaccine Taskforce originally secured 30 million doses of the vaccine – also known as the Janssen COVID-19 vaccine – the UK has amended the amount and is now set ... The Janssen vaccine will be another weapon in our arsenal to beat
J&J’s COVID-19 vaccine shows ‘strong’ activity against Delta variant
CHMP recommends eight new medicines for EU approval
More from news
Approximately 140 fully matching, plus 410 partially matching documents found.
Latest Intelligence
-
Understanding the ‘real world’ starts and ends with the patient
For the past 20 years, true understanding of the patient experience has been the turnkey for R&D for therapies in pulmonary arterial hypertension (PAH) at Janssen Pulmonary Hypertension (following the ... PAH treatment strategies or interventions, an
-
Unlocking the potential of precision medicine in oncology
Joaquín Casariego García-Lubén talks to PME about how Janssen is driven by the premise of providing personalised treatment solutions in cancer care. ... Joaquín Casariego García-Lubén is EMEA Therapeutic Area Lead Oncology, The Janssen
-
Switzerland: a life sciences hub
The country is thus home to AbbVie, Allergan, Amgen, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Eli Lilly, Gilead, GlaxoSmithKline, Janssen, Lundbeck, MSD (Merck Sharp &Dohme), Pfizer, Sanofi and Takeda among others.
-
Will biosimilars ever catch on in the US?
Pfizer also cited a Janssen brochure that allegedly implied the biosimilar Inflectra is not interchangeable with Remicade and may pose a safety risk.
-
The first, my last, my everything
It’s a subtle but important nuance. It’s a similar story elsewhere, with companies like Roche, Janssen and MSD ‘partnering with patients’ to understand their needs and identify opportunities for
Understanding the ‘real world’ starts and ends with the patient
Unlocking the potential of precision medicine in oncology
Switzerland: a life sciences hub
Will biosimilars ever catch on in the US?
The first, my last, my everything
More from intelligence
Approximately 5 fully matching, plus 53 partially matching documents found.
Latest appointments
-
Genmab appoints Tahamtan Ahmadi as chief medical officer, head of experimental medicines
Prior to Genmab, Ahmadi worked as head of experimental medicine and early development oncology at Janssen.
-
Ex-J&J exec Denice Torres joins bluebird bio’s board
During her time at J&J, Torres held several executive leadership roles including president of McNeil Consumer Healthcare and president of Janssen Pharmaceuticals, CNS.
-
New hires at Bristol-Myers Squibb, Acceleron and FerGene
He has also served in various executive leadership roles at Novartis Pharma and Novartis Oncology, and he began his career at Johnson &Johnson and Janssen.
-
Robert Freisen joins Ablynx
He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.
-
Mundipharma appoints Dr Alberto Martinez as president and CEO
Prior to his time at Mundipharma, he served Napp Pharmaceuticals and Janssen in various capacities.
Genmab appoints Tahamtan Ahmadi as chief medical officer, head of experimental medicines
Ex-J&J exec Denice Torres joins bluebird bio’s board
New hires at Bristol-Myers Squibb, Acceleron and FerGene
Robert Freisen joins Ablynx
Mundipharma appoints Dr Alberto Martinez as president and CEO
More from appointments
Approximately 3 fully matching, plus 27 partially matching documents found.
Latest from PMHub
-
OPEN Health’s Learning & Development team have won a Bronze Award at the PM Society Digital Awards 2020
READ MORE ABOUT OUR WINNING PROJECT WITH WITH JANSSEN BELOW:. The Immunology Training Summit (ITS) 2020 with the Janssen EMEA Immunology team took a week-long face-to-face meeting for ... Strikingly this format is now considered best practice in
-
Mednet Group
Clinigen. Crohns and Colitis Department for International Development. Eisai. Gilead. Janssen.
-
If our patients are diverse, why are clinical trials so white?
Darzalex is made by Janssen Oncology, a company under Johnson &Johnson. ... Janssen are not alone in trying to make clinical trials more representative.
-
Havas Lynx Group
Grϋnenthal. Janssen. Lilly. Lundbeck. Merck Serono. Novartis. Novo Nordisk. Pfizer. Roche.
-
EPG Health
Strategic planning - to ensure ongoing engagement and success. Alexion, Almirall, Alnylam, AstraZeneca, Bial, Biogen, Bluebird Bio, Boehringer Ingelheim, BMS, CSL Behring, Ferring, Four Health, GSK, HRA Pharma, Janssen, Leo Pharma, Lilly,
Mednet Group
Havas Lynx Group
EPG Health
More from PMHub
Approximately 5 fully matching, plus 28 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Senior Consultant, Pricing & Market Access Consultancy, circ...
-
circa £100K package
-
Digital account director
-
Competitive
-
Events Executive
-
Depending on Experience
- Principal/ Senior/ Medical Writer – Global Med Ed and Comms Agen...
-
Highly competitive salary
- Project Director, Healthcare Marketing Agency patient focus Lond...
-
Highly competitive salary
- Account Manager - Healthcare Consultancy
-
Salary depending on experience
- Digital Project Director, Healthcare Marketing Agency patient fo...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- Mixing AZ and Pfizer COVID-19 vaccines increases antibody levels
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- CHMP rejects Kyowa Kirin’s Parkinson’s disease drug
- Google’s DeepMind opens ‘breakthrough’ protein database to the world
- AZ publishes new real-world safety data for COVID-19 vaccine Vaxzevria
- Merck & Co’s sales bounce back in ‘ongoing recovery from COVID-19’
- Lilly and Kumquat Biosciences link up in $2bn-plus immuno-oncology deal
- Michael J. Fox Foundation and IBM reveal new AI model for Parkinson’s disease
- BMS’ Q2 results beat expectations with strong performance across core therapy areas
- Amanda Pritchard becomes NHS England’s first female chief executive
- Understanding the ‘real world’ starts and ends with the patient
- Onyx Health Launch Creative Studio After Record Year
- BioNTech plans acquisition of Kite’s TCR cell therapy R&D platform
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
- Tonix Pharmaceuticals to develop TNX-102 for long COVID syndrome
- Migraine-friendly colours for the home
PMHub
Hanover Communications
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...
Latest intelligence
- Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
- The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
- Employee wellbeing in creative agencies: three tips to get you started
- Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
- Managing unhelpful pressure in your creative agency: the human approach
- Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...
